Biomarker for prognosis of thyroid cancer
AssigneeNational Taiwan University
InventorsChih-Yuan Wang, Tien-Chun Chang, Pei-Jie Huang
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method of prognosis of thyroid cancer including obtaining an exosome from a subject who had received a therapy of thyroid cancer such as thyroidectomy, and detecting whether thyroglobulin is present in the exosome. Moreover, the present disclosure provides the use of urinary exosomal thyroglobulin in being a non-invasive, reproducible, convenient, serial, and accurate follow-up marker for patient with thyroid cancer.
Claims11
A method of prognosis of thyroid cancer in a subject in need thereof, comprising:
- obtaining an exosome from the subject who had received a therapy of thyroid cancer, wherein the exosome is isolated from urine;
- detecting a trend of a level of thyroglobulin present in the exosome;
- diagnosing the subject with recurrent thyroid cancer for prognosis when the presence of thyroglobulin in the exosome shows an increasing trend,
- wherein the increasing trend is that within six months after the therapy of thyroid cancer, a serum thyroglobulin of the diagnosed subject is undetectable, while the urinary exosomal thyroglobulin of the diagnosed subject is detected at a level of 0.412 ng/mL to 9.29 ng/ml;
- and
- administering a thyroid cancer treatment to the diagnosed subject.
A method of evaluating a therapy of thyroid cancer, comprising:
- obtaining an exosome from a subject who had received the therapy of thyroid cancer, wherein the exosome is isolated from urine;
- detecting a trend of a level of thyroglobulin present in the exosome,
- wherein the level of thyroglobulin in the exosome is indicative of the efficacy of the therapy of thyroid cancer,
- wherein the thyroglobulin showing an increasing trend in the exosome is indicative of thyroid cancer recurrence,
- wherein the increasing trend is that within six months after the therapy of thyroid cancer, a serum thyroglobulin of the subject is undetectable, while the urinary exosomal thyroglobulin of the subject is detected at a level of 0.412 ng/ml to 9.29 ng/ml;
- and
- administering a thyroid cancer treatment to the subject when the presence of thyroglobulin in the exosome is detected.
Dependencies are inferred from the claim text.